Weekly RSV Vaccination Dashboard

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among adults 75 years and older and 60─74 years with high-risk conditions for RSV are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Data and charts are available here.

As of December 7, 2024, among adults ≥75 years:

• An estimated 42.5% (95% Confidence Interval: 40.1%─45.0%) reported having ever received an RSV vaccine.
  • An additional 7.3% (4.1%─10.5%) reported they definitely will get a vaccine,
    
• Vaccination coverage varied by poverty status, race and ethnicity, urbanicity, and presence of a chronic medical condition.
• Additional RSV vaccination data by demographic characteristics at the national and regional level are available.

As of December 7, 2024, among adults 60─74 years with a high-risk condition for RSV:

• An estimated 33.0% (30.1%─35.9%) reported having ever received an RSV vaccine.
  • An additional 9.8% (6.6%─13.0%) reported they definitely will get a vaccine.
• Vaccination coverage varied by disability status, health insurance status, poverty status, and race and ethnicity.
• Additional RSV vaccination data by demographic characteristics at the national and regional level are available.

Adults 75+ RSV Vaccination Administration and Coverage (monthly)

RSV vaccination coverage estimates among adults 75 years and older as of the end of November 2024 based on IIS data submitted to CDC by 44 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available here.

• Among the currently reporting 36 state and city IIS jurisdictions, RSV vaccination coverage among adults 75 years and older ranged from1.5% to 42.9%. Among 8 U.S. territorial and affiliated island jurisdictions, coverage ranged from 0.0% to 2.9%.

Adults 75+ RSV Vaccination Coverage (monthly)

RSV vaccination coverage among Medicare fee-for-service beneficiaries 75 years and older and enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service administrative claims data managed by the Centers for Medicare & Medicaid Services. Data and charts are available here.

• As of September 28, 2024, an estimated 25.7% of Medicare fee-for-service beneficiaries 75 years and older enrolled in Part D plan were vaccinated.
• Vaccination coverage was highest among White, non-Hispanic beneficiaries (26.6%) and lowest among Hispanic beneficiaries (7.8%).

Adults 75+ RSV Vaccinations Administered

IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for adults 75 years and older, based on healthcare claims data. Data and charts are available here.

• During August 12, 2023, through November 23, 2024, among adults ≥75 years:
  • An estimated ~5.63 million doses of RSV vaccine were administered in retail pharmacies. Of these, an estimated ~1.13 doses were administered since August 4, 2024.
  • An estimated 116,655 doses of RSV vaccine were administered in physicians’ medical offices. Of these, an estimated 26,315 doses were administered since August 4, 2024.

Pregnant Women RSV Vaccination Coverage

Estimates of RSV vaccination coverage for pregnant women 18─49 years are calculated using data from CDC's Vaccine Safety Datalink (VSD). VSD data includes electronic health records data from ten integrated health systems. Data and charts are available here.

• As of December 7, 2024, among women who were pregnant and at least 32 weeks gestation since September 1, 2024, overall coverage with the RSV vaccine was 34.5%.
• Vaccination coverage was highest among non-Hispanic Asian (47.1%) pregnant women and lowest among non-Hispanic Black (23.2%) pregnant women.

Nirsevimab Coverage and Intent for Infants (monthly)

Monthly estimates of infant protection against RSV by maternal RSV vaccination or receipt of nirsevimab, as well as intent for nirsevimab receipt, reported by females age 18─49 years with infants <8 months during the RSV season (born since April 1, 2024) are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report. Data and charts are available here.

• As of November 2024, among females with an infant born since April 1, 44.7% of infants were reported to be protected against RSV through either maternal immunization only (6.7%) or receipt of nirsevimab (38.0%), and an additional 17.9% reported that they would definitely get nirsevimab for their infants.

Nirsevimab Administration and Coverage for Infants (monthly)

Nirsevimab administration and coverage estimates among infants <8 months (born since April 1, 2024) as of the end of November 2024 based on IIS data submitted to CDC by 44 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available here.

• Among the currently reporting 36 state and city IIS jurisdictions, nirsevimab coverage among infants <8 months (born since April 1) ranged from 13.6% to 43.7%. Among 8 U.S. territorial and affiliated island jurisdictions, coverage ranged from 0.0% to 29.9%.